Pedro P España1, Alberto Capelastegui2, Carmen Mar3, Amaia Bilbao4, José M Quintana5, Rosa Diez2, Cristobal Esteban2, Edurne Bereciartua3, Unai Unanue3, Ane Uranga2. 1. Pneumology Service, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain. Electronic address: pedropablo.espanayandiola@osakidetza.net. 2. Pneumology Service, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain. 3. Biochemistry Service, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain. 4. Research Unit, Basurto University Hospital (Osakidetza) - Health Services Research on Chronic Patients Network (REDISSEC), Bilbao, Bizkaia, Spain. 5. Research Unit, Hospital Galdakao-Usansolo - REDISSEC, Galdakao, Bizkaia, Spain.
Abstract
BACKGROUND: We sought to evaluate the usefulness of biomarkers-procalcitonin (PCT), C-reactive protein (CRP) and proadrenomedullin (pro-ADM)-combined with prognostic scales (PSI, CURB-65 and SCAP score) for identifying adverse outcomes in patients with community-acquired pneumonia (CAP) attending at an Emergency Department (ED). METHODS: Prospective observational study in a teaching hospital among patients with CAP. In addition to collecting data for the prognostic scales, samples were taken at the ED for assessing PCT, CRP and pro-ADM levels. We compared the prognostic accuracy of these biomarkers with severity scores to predict pneumonia related complications, using the area under the receiver operating characteristics curves (AUC), which evaluates how well the model discriminate between patients who had a pneumonia related complication or not. RESULTS: A total of 491 patients with CAP were enrolled, 256 being admitted to the hospital and 235 treated as outpatients. Admitted patients had higher biomarker levels than outpatients (p < 0.001). The SCAP score and pro-ADM level had the best AUCs for predicting pneumonia related complications (0.83 and 0.84, respectively). Considering SCAP score plus pro-ADM level, the AUC increased significantly to 0.88. SCAP score class 0 or 1 with a pro-ADM level <0.5 ng/mL was the best indicator for selecting patients for outpatient care. CONCLUSIONS: A new risk score combining SCAP score with pro-ADM level is useful to classify severity risk in CAP patients and hence supporting decision-making on hospital admission.
BACKGROUND: We sought to evaluate the usefulness of biomarkers-procalcitonin (PCT), C-reactive protein (CRP) and proadrenomedullin (pro-ADM)-combined with prognostic scales (PSI, CURB-65 and SCAP score) for identifying adverse outcomes in patients with community-acquired pneumonia (CAP) attending at an Emergency Department (ED). METHODS: Prospective observational study in a teaching hospital among patients with CAP. In addition to collecting data for the prognostic scales, samples were taken at the ED for assessing PCT, CRP and pro-ADM levels. We compared the prognostic accuracy of these biomarkers with severity scores to predict pneumonia related complications, using the area under the receiver operating characteristics curves (AUC), which evaluates how well the model discriminate between patients who had a pneumonia related complication or not. RESULTS: A total of 491 patients with CAP were enrolled, 256 being admitted to the hospital and 235 treated as outpatients. Admitted patients had higher biomarker levels than outpatients (p < 0.001). The SCAP score and pro-ADM level had the best AUCs for predicting pneumonia related complications (0.83 and 0.84, respectively). Considering SCAP score plus pro-ADM level, the AUC increased significantly to 0.88. SCAP score class 0 or 1 with a pro-ADM level <0.5 ng/mL was the best indicator for selecting patients for outpatient care. CONCLUSIONS: A new risk score combining SCAP score with pro-ADM level is useful to classify severity risk in CAPpatients and hence supporting decision-making on hospital admission.
Authors: Katherine Adams; Mark W Tenforde; Shreya Chodisetty; Benjamin Lee; Eric J Chow; Wesley H Self; Manish M Patel Journal: Hum Vaccin Immunother Date: 2021-11-10 Impact factor: 3.452
Authors: Jose Curbelo; Sergio Luquero Bueno; José María Galván-Román; Mara Ortega-Gómez; Olga Rajas; Guillermo Fernández-Jiménez; Lorena Vega-Piris; Francisco Rodríguez-Salvanes; Belén Arnalich; Ana Díaz; Ramón Costa; Hortensia de la Fuente; Ángel Lancho; Carmen Suárez; Julio Ancochea; Javier Aspa Journal: PLoS One Date: 2017-03-16 Impact factor: 3.240
Authors: Kordo Saeed; Darius Cameron Wilson; Frank Bloos; Philipp Schuetz; Yuri van der Does; Olle Melander; Pierre Hausfater; Jacopo M Legramante; Yann-Erick Claessens; Deveendra Amin; Mari Rosenqvist; Graham White; Beat Mueller; Maarten Limper; Carlota Clemente Callejo; Antonella Brandi; Marc-Alexis Macchi; Nicholas Cortes; Alexander Kutz; Peter Patka; María Cecilia Yañez; Sergio Bernardini; Nathalie Beau; Matthew Dryden; Eric C M van Gorp; Marilena Minieri; Louisa Chan; Pleunie P M Rood; Juan Gonzalez Del Castillo Journal: Crit Care Date: 2019-02-08 Impact factor: 9.097
Authors: Todd A Florin; Lilliam Ambroggio; Cole Brokamp; Yin Zhang; Eric S Nylen; Mantosh Rattan; Eric Crotty; Michael A Belsky; Sara Krueger; Thomas N Epperson; Andrea Kachelmeyer; Richard M Ruddy; Samir S Shah Journal: Clin Infect Dis Date: 2021-08-02 Impact factor: 9.079